TheraSyn Bio
TheraSyn Bio is a Massachusetts-based preclinical synthetic biology company developing precision therapeutics through Project Panacea, a breast cancer topical therapy advanced via a joint venture with Rubix LS on an AI-augmented bioscience platform.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What TheraSyn Bio does
TheraSyn Bio (TSB) is a Massachusetts-incorporated, privately held synthetic biology company founded in 2022 and headquartered in Lawrence, near the Cambridge innovation corridor. It operates an Integrated Bioscience Innovation Platform that the company describes as combining synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational bioscience research. The platform spans three stated pillars: Patient Therapies, Environmental Science, and Agriscience. The company's flagship initiative is Project Panacea, a preclinical program developing a localized, topical precision therapy for breast cancer intended to improve therapeutic efficacy while reducing systemic toxicity. Project Panacea is being advanced through a joint venture with Rubix LS, which contributes real-world patient data and clinical research expertise, while TSB contributes bioengineering capabilities. The company is explicitly pre-commercial: no products are approved or generating revenue, no funding rounds are disclosed, and headcount is reported in the 1-10 range.
TheraSyn Bio's commercial posture is enterprise-led and partnership-driven rather than product-sales-driven. Revenue mechanics, as disclosed, contemplate two streams: (i) therapeutic development and licensing, where Project Panacea and successor programs could be licensed to pharmaceutical partners, and (ii) platform services and partnerships, through collaborative research with universities, healthcare organizations, agricultural research institutions, government agencies, and environmental organizations globally. Pricing is not publicly disclosed, consistent with a preclinical R&D-stage company. Named historical relationships include NIH, HHS, CMS, VA Medical, and unspecified pharma partners, though the input does not establish whether these are active contracts, past engagements, or background of team members.
The company is registered as a trademark and 100% US-owned corporation, with publicly disclosed government identifiers (UEI X28FBXVY5J98, Cage Code 9CDTO) suggesting potential federal contracting eligibility. No patents, regulatory clearances, certifications, executive team bios, or funding rounds are disclosed in the input data, and the management team roster is empty. The website is built on GoDaddy infrastructure with a single English-language site, a LinkedIn presence, and an email newsletter as primary marketing channels. Substantive evidence of operational scale — payments, signed contracts, employee count detail, named investors — is absent.
TheraSyn Bio firmographics
Firmographics- Name
- TheraSyn Bio
- Legal name
- TheraSyn Bio Inc
- Website
- https://therasynbio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TheraSyn Bio is a Massachusetts-based preclinical synthetic biology company developing precision therapeutics through Project Panacea, a breast cancer topical therapy advanced via a joint venture with Rubix LS on an AI-augmented bioscience platform.
- Ownership category
- akta.pro rank
TheraSyn Bio industry classification
Industry- Product category
- Precision Bioscience & Synthetic Biology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where TheraSyn Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TheraSyn Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Development and Licensing: Development of next-generation precision therapeutics including Project Panacea for breast cancer and women's health, with potential for licensing outcomes to pharmaceutical partners
- Platform Services and Partnerships: Collaborative research services with industry leaders, academic institutions, and strategic partners across healthcare, environmental science, and agriculture sectors
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
TheraSyn Bio product offering
Product offeringCore offering
TheraSyn Bio operates an AI-augmented Integrated Bioscience Innovation Platform that combines synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational digital development of bioscience research. Its flagship initiative, Project Panacea, is a joint venture with Rubix LS advancing a localized, precision-based topical therapy for breast cancer and women's health. The platform also extends to environmental science and agriscience applications.
Product overview
TheraSyn Bio is a digital technology company operating a unified integrated bioscience innovation platform augmented by AI to target precision bioscience. The company offers its core Integrated Bioscience Innovation Platform, which enables AI-powered sample characterization and computational digital development of bioscience research. The platform's flagship initiative is Project Panacea, a therapeutic development program focused on breast cancer and women's health. The platform strategy spans three strategic pillars: Patient Therapies, Environmental Science, and Agriscience, all connected through synthetic biology, AI, and translational research capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated Bioscience Innovation Platform
- Project Panacea
Quantifiable outcome
- Localized precision-based therapeutic development designed to improve therapeutic efficacy while reducing systemic toxicity
Companies that use TheraSyn Bio
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
TheraSyn Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
TheraSyn Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Rubix LSflagshipJoint venture collaboration for Project Panacea, TheraSyn Bio's flagship initiative advancing innovative approaches for breast cancer and women's health. This collaboration unites TSB's bioengineering expertise with Rubix LS's extensive real-world patient data insights to create a localized, precision-based treatment that enhances therapeutic efficacy while minimizing systemic toxicity. The venture integrates synthetic biology with patient-centric data analytics for preclinical research evaluating safety, efficacy, and feasibility of a novel topical therapy for breast cancer.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
TheraSyn Bio competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Computational chemistry and biology platform serving pharma and biotech with molecular simulation and AI tools. Overlaps with TheraSyn Bio's AI-augmented bioscience approach but operates at a much broader scale.
- Benchling: Cloud-based life sciences R&D platform used for biological data management, molecular design, and lab workflows. Comparable as an integrated bioscience platform serving therapeutic developers.
- Tempus AI: Precision medicine platform leveraging AI and large real-world clinical/molecular datasets to advance oncology therapeutics. Comparable in combining AI with patient-centric data for precision oncology, similar to the Rubix LS partnership angle.
Direct peers
- Lantern Pharma: AI-driven oncology drug development company using machine learning to identify and develop precision cancer therapies. Comparable in applying AI and patient data analytics to precision oncology.
- Exscientia: AI-driven precision medicine company applying computational design to drug discovery, particularly in oncology. Comparable to Project Panacea's AI-driven precision oncology focus.
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate therapeutic development. Directly comparable to TheraSyn Bio in applying AI and biology to precision therapeutics.
- Ginkgo Bioworks: Synthetic biology platform company engineering organisms for healthcare, agriculture, and industrial applications. Closely matches TheraSyn Bio's synthetic biology platform approach across multiple verticals.
- Recursion Pharmaceuticals: AI-enabled biotech using computational tools and high-dimensional biology to discover and develop precision medicines. Comparable in integrating AI, biology, and translational research pipelines.
Emerging players
- Owkin: AI biotech company combining multimodal patient data and AI for drug discovery and development, with oncology focus. Comparable in applying AI to real-world patient data for precision therapeutic development.
- Cradle Bio: AI-powered protein engineering platform for synthetic biology applications. Comparable in combining generative AI with synthetic biology for therapeutic and industrial use cases.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
TheraSyn Bio social profiles
Digital presenceTheraSyn Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraSyn Bio leadership team
Management profileNumber of profiles
Profiles1 record
TheraSyn Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraSyn Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraSyn Bio
What does TheraSyn Bio do?
TheraSyn Bio operates an AI-augmented Integrated Bioscience Innovation Platform that combines synthetic biology, artificial intelligence, and translational research to characterize biological samples and support computational digital development of bioscience research. Its flagship initiative, Project Panacea, is a joint venture with Rubix LS advancing a localized, precision-based topical therapy for breast cancer and women's health. The platform also extends to environmental science and agriscience applications.
Is TheraSyn Bio a public or private company?
TheraSyn Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TheraSyn Bio founded?
TheraSyn Bio was founded in 2022. It employs 1 to 10 people.
Where is TheraSyn Bio based?
TheraSyn Bio is headquartered in Cambridge, United States, in the North America region.
How does TheraSyn Bio make money?
Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are platform Services and Partnerships.
Who are TheraSyn Bio's main competitors?
Broad incumbents on record are Schrödinger, Benchling and Tempus AI. Direct peers are Lantern Pharma, Exscientia, Insitro, Ginkgo Bioworks and Recursion Pharmaceuticals. Emerging players are Owkin and Cradle Bio.
Does TheraSyn Bio have an API?
No public API is recorded for TheraSyn Bio.
What industry is TheraSyn Bio in?
TheraSyn Bio's product category is Precision Bioscience & Synthetic Biology Therapeutics. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.